装备制造 [Table_ReportDate] 2026 年 01 月 26 日 [T分析师： able_Author 赵晓闯] 执业证书号：S1030511010004 电话：0755-83199599 邮箱：zhaoxc@csco.com.cn 分析师：杨贵洲 执业证书号：S1030524060001 电话：0755-83199599 邮箱：yanggz1@csco.com.cn 研究助理：董李延楠 证券研究报告 固态电池产业持续推进 [Table_ReportType]装备制造行业周报（1 月第 3 周） [Table_S 市场行情回顾 ummary] ： 上周 5 个交易日机械设备、电力设备及汽车行业指数涨跌幅 分别为+2.56%、+3.57%及+2.51%，在 31 个申万一级行业中排 名分别为第 13、11、14 位；同期沪深 300 涨跌幅为-0.62%。 行业观点： 4) 风险提示：宏观经济风险、产业政策风险、行业竞争加剧风险。 请务必阅读文后重要声明及免责条款 电话：0755-83199599 邮箱：donglyn@csco.com.cn 公司具备证券投资咨询业务资格 [Table_Indu ...

装备制造 [Table_ReportDate] 2026 年 01 月 26 日 [T分析师： able_Author 赵晓闯] 执业证书号：S1030511010004 电话：0755-83199599 邮箱：zhaoxc@csco.com.cn 分析师：杨贵洲 执业证书号：S1030524060001 研究助理：董李延楠 电话：0755-83199599 邮箱：donglyn@csco.com.cn 公司具备证券投资咨询业务资格 证券研究报告 固态电池产业持续推进 [Table_ReportType]装备制造行业周报（1 月第 3 周） [Table_S 市场行情回顾 ummary] ： 上周 5 个交易日机械设备、电力设备及汽车行业指数涨跌幅 分别为+2.56%、+3.57%及+2.51%，在 31 个申万一级行业中排 名分别为第 13、11、14 位；同期沪深 300 涨跌幅为-0.62%。 行业观点： 电话：0755-83199599 邮箱：yanggz1@csco.com.cn 4) 风险提示：宏观经济风险、产业政策风险、行业竞争加剧风险。 请务必阅读文后重要声明及免责条款 [Table_Indu ...

Investment Rating - The report does not explicitly state an investment rating for the industry [2]. Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 0.39% from January 19 to January 23, underperforming compared to the Wind All A index, which rose by 1.81% [3][8]. - Key segments such as offline pharmacies (up 9.66%), raw materials (up 2.41%), and pharmaceutical distribution (up 2.28%) showed positive performance, while medical R&D outsourcing (down 3.96%), chemical preparations (down 1.74%), and medical devices (down 0.7%) lagged behind [3][9]. - The personalized tumor vaccine is expected to trigger a significant shift in whole exome sequencing (WES) technology, with Moderna's mRNA personalized tumor vaccine showing a nearly 50% reduction in recurrence or death risk compared to Keytruda alone, based on five-year follow-up data [3][12]. - The report emphasizes the importance of high-quality WES data for the efficacy of mRNA personalized tumor vaccines, suggesting that once validated, WES will transition from an optional to a mandatory diagnostic tool, leading to a value reconstruction in the upstream sequencing industry [3][12]. Market Weekly Review - The pharmaceutical and biotechnology sector's performance from January 19 to January 23 showed a decline of 0.39%, underperforming the Wind All A index, which increased by 1.81% [8]. - Notable gainers included *ST Changyao (up 70.4%), Hualan Biological Engineering (up 32.2%), and Tianzhihang-U (up 27.7%), while major losers were Sunflower (down 37.5%), *ST Changyao (down 33.3%), and Luyuan Pharmaceutical (down 26.6%) [11][12]. Industry News and Key Company Announcements - On January 20, the National Healthcare Security Administration released guidelines for pricing medical services related to surgical and treatment auxiliary operations, which has garnered significant attention in the medical industry [11]. - Moderna and Merck announced that their personalized mRNA vaccine mRNA-4157, in combination with Keytruda, significantly improved recurrence-free survival in high-risk melanoma patients, reducing the risk of recurrence or death by 49% [12][13]. - GSK announced a $2.2 billion acquisition of RAPT Therapeutics, which includes a monoclonal antibody currently in clinical development for food allergies [15]. - The report highlights various companies' performance forecasts, including a projected net profit of -900 million to -995 million for Maiwei Bio, and a significant increase in revenue for JianKai Technology, with expected net profit growth of 101.09% to 121.20% [15][16].

Investment Rating - The report does not explicitly state an investment rating for the industry, but it suggests a positive outlook for Alibaba and related sectors, indicating a favorable investment environment [2]. Core Insights - Alibaba's "Qianwen" product launch signifies a shift in AI capabilities from a "Q&A assistant" to a "task executor," integrating over 400 functions across its ecosystem, which is expected to enhance user engagement and commercial viability [3][5]. - The emergence of the GEO (Generative Engine Optimization) business model is transforming marketing strategies, shifting focus from SEO to GEO, which is anticipated to benefit marketing agencies and authoritative media platforms while traditional traffic platforms may face challenges [3][5]. - The TMT sector showed a strong performance in the week of January 12-16, with notable gains in sub-sectors such as portal websites and semiconductor equipment, outperforming the broader market [3][5]. Market Weekly Review - The TMT sector's performance from January 12-16 showed a rise in the computer sector by 3.82%, electronics by 3.77%, media by 2.04%, and communication by 1.42%, collectively outperforming the CSI 300 index, which fell by 0.57% [3][5]. - The top-performing sub-industries included portal websites (17.69% increase), integrated circuit packaging and testing (14.47% increase), and semiconductor equipment (9.31% increase) [3][5]. Industry News and Key Company Announcements - Alibaba's "Qianwen" product launch on January 15 is a significant event, showcasing its AI capabilities and integration with various services [3][5]. - The report highlights the rapid growth of the "Qianwen" app, which achieved over 100 million monthly active users within two months of launch, indicating strong market acceptance [3][5]. - The report notes that the GEO model is expected to enhance the profitability of marketing agencies and elevate the status of authoritative media platforms, while traditional traffic platforms may experience a decline [3][5].

Investment Rating - The report indicates a positive investment outlook for the pharmaceutical and biotechnology sector, with a focus on AI-enabled strategic upgrades in pharmaceutical manufacturing [2]. Core Insights - The pharmaceutical and biotechnology sector experienced a 5.6% increase from December 29, 2025, to January 9, 2026, outperforming the Wind All A index (4.76%) and the CSI 300 index (2.18%). Key segments leading this growth include hospitals (12.95%), medical research outsourcing (9.25%), and medical devices (7.96%) [2][7]. - The report highlights the rapid development of AI in healthcare, emphasizing the government's initiative to foster AI in drug development, supply chain management, surgical robotics, and intelligent diagnostic systems by 2027. This initiative aims to cultivate 2-3 leading ecological enterprises and a number of specialized companies [2][11]. - The upcoming JPM Healthcare Conference from January 12 to 15, 2026, is expected to boost the sentiment in the innovative drug sector, with over 500 listed companies and thousands of startups participating [2][11]. Market Weekly Review - The pharmaceutical and biotechnology sector rose by 5.6% during the last interval, with hospitals, medical research outsourcing, and medical devices leading the gains. Notably, the stock of Sanbo Brain Science surged by 63.53%, while *ST Changyao saw a decline of 44.9% [7][10]. - The report provides detailed performance metrics for various sub-sectors, with hospitals showing a 12.95% increase, medical research outsourcing at 9.25%, and medical devices at 7.96% [8][9]. Industry News and Key Company Announcements - On January 7, eight departments jointly issued the "AI + Manufacturing" action plan, marking AI drug development and medical supply chain intelligence as national priorities [11]. - Notable company announcements include: - Yilian Bio's exclusive licensing agreement with Roche for the YL201 project, which includes a $570 million upfront payment [11]. - Merck's discussions to acquire Revolution Medicines for $28 billion to $32 billion [11]. - Structure Therapeutics' agreement with Roche and Genentech for a non-exclusive patent license, resulting in a $100 million upfront payment [11][12]. - Eli Lilly's acquisition of Ventyx Biosciences for $1.2 billion [14].

Macroeconomic Overview - December PMI showed a seasonal rebound, indicating expectations for policy support in the coming year, particularly in the construction sector[2] - December CPI and PPI were 0.8% and -1.9% year-on-year, respectively, both exceeding expectations, with a month-on-month increase of 0.2%[2] - The first batch of special government bonds for 2026, amounting to 62.5 billion yuan, was issued earlier than in 2025, supporting consumer policies[2] Financial Market Performance - From December 29, 2025, to January 9, 2026, the equity market saw a significant increase, with daily trading volume averaging 25,806 billion yuan, up 6,154 billion yuan from the previous period[2] - The Shanghai Composite Index rose by 3.95%, while the Shenzhen Component Index increased by 3.79%[2] Fixed Income Market - Bond yields rose overall during the same period, with the 10-year government bond yield increasing by 5.1 basis points[2] - The central bank's net MLF injection of 100 billion yuan contributed to a stable and loose funding environment[2] International Market Dynamics - U.S. non-farm payrolls increased by 50,000 in December, below the expected 60,000, while the unemployment rate fell to 4.4%[2] - The U.S. dollar index rose by 1.12%, and oil prices increased due to geopolitical tensions, particularly regarding Venezuela[2] Risk Factors - Potential risks include weaker-than-expected fundamentals, slower-than-anticipated reserve requirement ratio cuts, and renewed inflation pressures in the U.S.[2]

Investment Rating - The report does not explicitly state an investment rating for the industry, but it suggests a positive outlook based on recent developments in the duty-free retail sector and domestic dairy industry [1]. Core Insights - The duty-free retail sales in Hainan have significantly increased following the implementation of the duty-free policy, with sales amounting to 1.1 billion yuan during the first week of operation, reflecting a year-on-year increase of 54.9% [3][15]. - The EU's preliminary anti-subsidy investigation into dairy products has led to the imposition of temporary anti-subsidy tax measures, which are expected to increase the import costs of EU dairy products, thereby benefiting domestic dairy producers [3][15]. - The consumer sector showed mixed performance in the last week of December, with textile and apparel, home appliances, and retail sectors showing positive growth, while food and beverage, social services, and beauty care sectors experienced declines [3][13]. Summary by Sections Market Weekly Review - The consumer sector exhibited varied performance, with textile and apparel (+0.61%), home appliances (+0.54%), and retail (+0.16%) showing gains, while food and beverage (-0.56%), social services (-1.05%), and beauty care (-1.08%) faced declines [3][5]. - Notable stock performances included Anji Food (+29.65%), Feike Electric (+24.57%), and Jujie Microfiber (+35.46%) leading the gains, while Huanle Home (-16.35%) and China High-Tech (-26.02%) were among the biggest losers [3][13]. Industry News and Key Company Announcements - The duty-free shopping in Hainan has shown a robust growth trend, with significant increases in shopping amounts and visitor numbers following the policy implementation [15][16]. - The report highlights the launch of the first Pop Mart store in the Philippines, indicating expansion into international markets [18]. - The report also notes various company announcements, including changes in housing policies in Beijing aimed at easing home purchase conditions for non-local families [18].

Investment Rating - The report does not explicitly state an investment rating for the industry, but it suggests a positive outlook for the medical device sector, indicating potential for growth and innovation [2][3]. Core Insights - The medical device sector is expected to enter a "great sailing era" with the initiation of centralized procurement for drug-coated balloons and urological intervention consumables, indicating a significant policy shift that could benefit domestic manufacturers [3]. - The report highlights that after extensive centralized procurement, domestic medical device manufacturers have gained substantial market share, leading to a concentration of the industry towards leading enterprises, which are expected to benefit from scale effects and favorable export policies [3]. - The report emphasizes the potential for domestic medical device companies to replicate the path of domestic pharmaceutical companies, using centralized procurement to drive innovation and enhance global competitiveness [3]. Market Weekly Review - The pharmaceutical and biotechnology sector experienced a slight decline of 0.18% from December 22 to December 26, underperforming compared to the Wind All A index (2.78%) and the CSI 300 index (1.95%) [8]. - Among sub-sectors, raw materials (2.05%), blood products (1.28%), and medical research outsourcing (0.77%) showed gains, while hospitals (-2.82%), pharmaceutical distribution (-1.8%), and offline pharmacies (-1.3%) faced declines [8]. - Notable individual stock performances included Hongyuan Pharmaceutical (59.4%), Luyuan Pharmaceutical (37.3%), and Huakang Medical (21.1%) with significant gains, while ST Bailin (-18.5%), Huaren Health (-15.8%), and Haiwang Biological (-14.9%) saw substantial losses [11]. Industry News and Key Company Announcements - The National Medical Products Administration announced new regulations for the management of medical device export sales certificates, effective May 1, 2026, which aims to facilitate the export of Chinese medical devices [13]. - The centralized procurement for high-value medical consumables has officially started, marking a significant policy development in the industry [13]. - Sanofi reached an acquisition agreement with Dynavax for $2.2 billion, highlighting ongoing consolidation in the pharmaceutical sector [13]. - Notable collaborations and agreements were reported, including licensing agreements and partnerships among various pharmaceutical companies, indicating active M&A and collaboration trends in the industry [16][17].

Investment Rating - The report does not explicitly state an investment rating for the industry [2]. Core Insights - The pathology business is entering a fast track with the National Healthcare Security Administration issuing guidelines for pricing projects in pathology services, focusing on biopsy sampling, sample processing, and digitalization of pathology data, which is expected to enhance the application of AI in the field [3][11]. - The influenza activity has peaked across the board, with reported cases in southern provinces at 9.7%, down from 11.2% the previous week, but higher than the same period in previous years [3][11]. Market Weekly Review - The pharmaceutical and biotechnology sector fell by 0.14% from December 15 to December 19, outperforming the Wind All A index (-0.15%) and the CSI 300 index (-0.28%). The rebound was weak, with segments like pharmaceutical distribution (5.59%), offline pharmacies (4.69%), and hospitals (4.15%) leading gains, while chemical preparations (-2.1%), vaccines (-0.87%), and medical R&D outsourcing (-0.87%) lagged [3][8]. - Notable stock performances included Huaren Health (55.9%), Luyuan Pharmaceutical (36.8%), and Shuyupingmin (35.7%) with significant gains, while *ST Changyao (-24%), Yipinhong (-23.7%), and Rejing Biology (-16.5%) faced substantial declines [3][11]. Industry News and Key Company Announcements - The National Healthcare Security Administration's guidelines for pathology services are expected to drive high-quality development in the sector and create new scenarios for AI-assisted technology applications [11]. - Significant collaborations and approvals were reported, including Shanghai Jinmante's partnership with Jiangsu Kangning Jerey for a breakthrough therapy designation from the FDA for JSKN003, and Novo Nordisk's submission of a marketing application for CagriSema, which showed a weight loss of 22.7% over 68 weeks in clinical trials [12][13]. - Fosun Pharma's subsidiary received FDA approval to initiate a Phase I clinical trial for HLX18, a biosimilar to Nivolumab, targeting various cancers [13][14].

Investment Rating - The report does not explicitly state an investment rating for the industry, but it suggests a focus on sectors with relatively low valuations such as liquor, hotels, catering, and duty-free segments, indicating a positive outlook for these areas [3]. Core Insights - The consumer sector faced a decline in the week of December 15-19, with various sub-sectors experiencing different levels of downturn, including retail and food and beverage [3]. - The launch of the Hainan Free Trade Port on December 18, 2025, is expected to significantly boost the duty-free industry, with the proportion of zero-tariff goods increasing from approximately 21% to 74%, enhancing product availability [3]. - Retail sales growth slowed in November, with total retail sales increasing by only 1.3% year-on-year, while policies aimed at expanding domestic demand are anticipated to aid recovery [3]. Summary by Sections Market Weekly Review - The consumer sector saw a broad decline, with specific weekly changes in various segments such as retail and food and beverage [3]. Industry News and Key Company Announcements - Hainan's duty-free shopping saw a significant increase in sales growth rates in September, October, and November, with respective year-on-year increases of 3.4%, 13.1%, and 27.1% [3]. - The report highlights the importance of expanding domestic demand as a strategic focus for the upcoming year, with the central economic work conference prioritizing this initiative [3]. - Key announcements include the IPO of Lin Qingxuan, which is expected to grow its revenue from 690 million yuan in 2022 to 1.21 billion yuan by 2024, reflecting a compound annual growth rate of 32.7% [15].